MedTrace Logo

Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults

NCT03895749 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-10-30

No results posted yet for this study

Summary

The nitric oxide supplementation product, Neo40 Daily®, provides a dietary source of No2-. The product also allows for robust No2-reduction to NO from the extremely potent nitrite-reducing capacity of the polyphenols found in Hawthorne berry.(Bartsch et al., 1993) Neo40 Daily® is a unique product since it provides the dietary source of No2-, as well as the rate limiting No2- reduction activity.

Conditions

Interventions

DIETARY_SUPPLEMENT

NEO40 Daily

Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.

Sponsors & Collaborators

  • Neogenis Laboratories

    collaborator OTHER

  • Hypertension Institute, Nashville

    lead OTHER

Principal Investigators

  • Mark Houston, MD · Hypertension Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-05
Primary Completion
2018-02-01
Completion
2018-04-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03895749 on ClinicalTrials.gov